Axa S.A. Has $5.70 Million Position in Illumina, Inc. (NASDAQ:ILMN)

AXA S.A. decreased its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 37.9% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,664 shares of the life sciences company's stock after selling 26,016 shares during the quarter. AXA S.A.'s holdings in Illumina were worth $5,701,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in ILMN. Versant Capital Management Inc lifted its position in Illumina by 153.7% during the 4th quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock worth $32,000 after acquiring an additional 146 shares during the period. Golden State Wealth Management LLC acquired a new stake in shares of Illumina during the fourth quarter worth about $32,000. Assetmark Inc. lifted its holdings in shares of Illumina by 954.8% during the fourth quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock worth $44,000 after purchasing an additional 296 shares during the period. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in Illumina in the fourth quarter valued at approximately $45,000. Finally, Lee Danner & Bass Inc. acquired a new position in Illumina in the 4th quarter worth approximately $48,000. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Price Performance

ILMN stock traded up $3.57 during trading on Monday, hitting $79.33. The company had a trading volume of 1,108,866 shares, compared to its average volume of 2,282,926. The business has a 50 day moving average of $78.94 and a 200 day moving average of $113.12. The firm has a market capitalization of $12.55 billion, a price-to-earnings ratio of -10.34, a P/E/G ratio of 1.60 and a beta of 1.35. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.96 by $0.01. The company had revenue of $1.04 billion for the quarter, compared to analysts' expectations of $1.03 billion. Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. The firm's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period last year, the firm earned $0.98 EPS. As a group, research analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Analysts Set New Price Targets

ILMN has been the subject of several analyst reports. Canaccord Genuity Group decreased their price objective on Illumina from $92.00 to $87.00 and set a "hold" rating for the company in a report on Monday. Robert W. Baird decreased their price target on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Royal Bank of Canada cut their price target on Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, April 8th. Barclays dropped their target price on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating on the stock in a research report on Thursday, April 10th. Finally, JPMorgan Chase & Co. decreased their price objective on Illumina from $120.00 to $85.00 and set a "neutral" rating on the stock in a report on Friday. One equities research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Illumina presently has an average rating of "Moderate Buy" and a consensus target price of $132.75.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.